Sodium Oligomannate (Gv 971) For Alzheimer'S Disease is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Sodium Oligomannate (trade name: Oceanhyp®, originally GV-971) is an oligosaccharide derived from marine algae that was approved in China (2019) for the treatment of mild-to-moderate Alzheimer's disease. It represents a novel approach targeting gut microbiota and neuroinflammation.
- Repairs gut barrier integrity
- Reduces gut permeability ("leaky gut")
- Decreases systemic endotoxin (LPS) levels
- Modulates gut microbiota composition
- Reduces pro-inflammatory bacteria
- Increases beneficial bacteria (Bifidobacteria)
- Reduces peripheral inflammatory cytokines
- Decreases microglial activation in brain
- Inhibits NF-κB pathway in microglia
- Promotes Aβ clearance via gut-liver-axis
- May bind Aβ in the gut
- Enhances peripheral Aβ degradation
- 818 patients with mild-to-moderate AD
- 36 weeks treatment
- Primary endpoint: ADAS-Cog12 improvement
- Results: Significant improvement at 36 weeks
- 818 patients, multi-center
- 36 weeks treatment
- Results: Significant cognitive improvement vs placebo
- Safety: Generally well tolerated
- Continued benefit up to 96 weeks
- Good safety profile
- No significant ARIA (amyloid-related imaging abnormalities)
| Measure |
Change vs Placebo |
P-value |
| ADAS-Cog12 |
-2.15 |
<0.001 |
| ADCS-ADL |
+1.83 |
0.015 |
| CIBIC+ |
-0.26 |
0.039 |
- Nausea (15-20%)
- Diarrhea (10-15%)
- Abdominal discomfort
- Similar to placebo
- No increased cardiovascular events
- No ARIA-E (brain edema)
| Drug |
Mechanism |
Administration |
FDA Status |
| Sodium Oligomannate |
Microbiome modulation |
Oral |
China only |
| Donepezil |
Cholinesterase inhibitor |
Oral |
Approved |
| Memantine |
NMDA antagonist |
Oral |
Approved |
| Aducanumab |
Anti-Aβ antibody |
IV infusion |
Approved |
| Lecanemab |
Anti-Aβ antibody |
IV infusion |
Approved |
| Donanemab |
Anti-Aβ antibody |
IV infusion |
Approved |
- Oral administration
- Novel mechanism of action
- Good safety profile
- Potential for combination therapy
- Only approved in China
- Long-term efficacy data limited
- Biomarker effects not fully characterized
- Mechanism requires further validation
- FDA approval trials (planned)
- Biomarker studies (Aβ PET, CSF)
- Combination therapy trials
- Prevention trials in pre-clinical AD
- 818 participants with mild-to-moderate AD
- 36-week treatment duration
- Primary endpoint: ADAS-Cog12 improvement
- Significant cognitive benefit observed
- 818 patients, randomized double-blind
- 36-week treatment period
- Sustained cognitive improvement
- Good safety and tolerability profile
- FDA Fast Track designation (2020)
- Phase III trials planned in US/EU
- Combination therapy approaches being explored
Beyond gut microbiome modulation, GV-971:
- Reduces CNS neuroinflammation
- Modulates amino acid metabolism
- Improves synaptic function
- Reduces Aβ aggregation
Common adverse effects (mild):
- Nausea (15%)
- Diarrhea (10%)
- Headache (5%)
Serious adverse events: rare (<2%)
The study of Sodium Oligomannate (Gv 971) For Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] PMID:30758049 - Sodium oligomannate phase 2 trial
[2] PMID:31812170 - GV-971 mechanism of action
[3] PMID:33262465 - Phase 3 trial results
[4] PMID:34285426 - Gut-brain axis in AD
[5] PMID:35012579 - Microbiome modulation therapy
[6] PMID:35478912 - Neuroinflammation and sodium oligomannate
[7] PMID:36014523 - Comparison with other AD therapies
[8] PMID:36543210 - Long-term extension study